Bayer begins $240m AI drug discovery project with Exscientia
10-01-2020
blackjack3d / iStockphoto.com
GSK has entered into a strategic drug discovery collaboration with an artificial intelligence-driven (AI) drug discovery company, Exscientia.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
GSK, Exscientia, collaboration, drug discovery, artificial intelligence, small molecules
